TP53 status and response to chemotherapy in breast cancer

被引：91

作者：

Bertheau, Philippe ^{[1
,2
]}

Espie, Marc ^{[3
]}

Turpin, Elisabeth ^{[4
,5
]}

Lehmann, Jacqueline ^{[4
,5
]}

Plassa, Louis-Francois ^{[4
,5
]}

Varna, Mariana ^{[2
]}

Janin, Anne ^{[2
]}

de The, Hugues ^{[4
,5
]}

机构：

[1] Hosp St Louis, APHP, Pathol Lab, Dept Pathol, FR-75010 Paris, France

[2] Univ Paris 07, INSERM, U728, Paris, France

[3] Hosp St Louis, APHP, Dept Oncol, FR-75010 Paris, France

[4] Hosp St Louis, APHP, Dept Biochem, FR-75010 Paris, France

[5] Univ Paris 07, CNRS, UMR7151, Paris, France

来源：

PATHOBIOLOGY | 2008年 / 75卷 / 02期

关键词：

p53; TP53; breast cancer; chemotherapy; anthracycline; taxanes; alkylating agents;

D O I：

10.1159/000123851

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Despite its central role in the control of apoptosis, senescence and cell cycle arrest, the tumor suppressor protein p53 remains an enigma for its possible role in predicting response to chemotherapy in cancer patients. Many studies remained inconclusive, others showed a better response for tumors with normal p53, and some recent studies showed adverse effects of normal p53 for response to treatment. p53 is not only a powerful pro-apoptotic factor in response to drug-induced DNA damages but also a potential inducer of cell cycle arrest, protecting tumor cells from further cytotoxic damages. Our review describes the classical as well as the more recent concepts. In order to draw definite conclusions, future works should use more reliable methods to assess the TP53 status and should address more homogeneous tumor subpopulations treated with homogeneous chemotherapy regimens. Copyright (c) 2008 S. Karger AG, Basel.

引用

页码：132 / 139

页数：8

共 76 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[3] Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF [J].

Andersson, J ;

Larsson, L ;

Klaar, S ;

Holmberg, L ;

Nilsson, J ;

Inganäs, M ;

Carlsson, G ;

Öhd, J ;

Rudenstam, CM ;

Gustavsson, B ;

Bergh, J .

ANNALS OF ONCOLOGY, 2005, 16 (05) :743-748

[4]

Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106

[5]

Bataille F, 2003, J CLIN PATHOL-MOL PA, V56, P286

[6] p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].

Bergamaschi, D ;

Gasco, M ;

Hiller, L ;

Sullivan, A ;

Syed, N ;

Trigiante, G ;

Yulug, I ;

Merlano, M ;

Numico, G ;

Comino, A ;

Attard, M ;

Reelfs, O ;

Gusterson, B ;

Bell, AK ;

Heath, V ;

Tavassoli, M ;

Farrell, PJ ;

Smith, P ;

Lu, X ;

Crook, T .

CANCER CELL, 2003, 3 (04) :387-402

[7]

Berns EMJJ, 2000, CANCER RES, V60, P2155

[8]

Bertheau P, 2005, ONCOL REP, V14, P513

[9] Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy [J].

Bertheau, P ;

Plassa, F ;

Espié, M ;

Turpin, E ;

de Roquancourt, A ;

Marty, M ;

Lerebours, F ;

Beuzard, Y ;

Janin, A ;

de Thé, H .

LANCET, 2002, 360 (9336) :852-854

[10] Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen [J].

Bertheau, Philippe ;

Turpin, Elisabeth ;

Rickman, David S. ;

Espie, Marc ;

de Reynies, Aurelien ;

Feugeas, Jean-Paul ;

Plassa, Louis-Francois ;

Soliman, Hany ;

Varna, Mariana ;

de Roquancourt, Anne ;

Lehmann-Che, Jacqueline ;

Beuzard, Yves ;

Marty, Michel ;

Misset, Jean-Louis ;

Janin, Anne ;

de The, Hugues .

PLOS MEDICINE, 2007, 4 (03) :585-594

← 1 2 3 4 5 6 7 8 →